
Major Breakthrough in Cystic Fibrosis Treatment: Sionna Therapeutics Sets Sights on IPO Success
Sionna Therapeutics aims to raise $150 million in its IPO by offering 8.8 million shares priced between $16 and $18. The company focuses on the cystic fibrosis transmembrane conductance regulator (CFTR) protein, targeting previously undruggable areas. Funds from the IPO will be